These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36880020)

  • 21. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
    Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
    Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
    [No Abstract]   [Full Text] [Related]  

  • 22. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
    Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.
    Haensli C; Pfister IB; Garweg JG
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34204266
    [No Abstract]   [Full Text] [Related]  

  • 24. Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol.
    Yoshida H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Takahashi H; Kawashima H; Yanagi Y
    Graefes Arch Clin Exp Ophthalmol; 2024 Jul; ():. PubMed ID: 38995352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
    Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
    Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
    Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world experience of brolucizumab in nAMD.
    Narnaware SH; Bansal A; Bawankule PK; Raje D
    Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S27-S32. PubMed ID: 38131538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
    Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Electrophysiological study of the visual pathway in anti-VEGF therapy of neovascular age-related macular degeneration combined with glaucoma].
    Smirnova TV; Rud'ko AS; Andreeva IV; Karpilova MA
    Vestn Oftalmol; 2019; 135(5):38-45. PubMed ID: 31714511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage.
    Maruyama-Inoue M; Kitajima Y; Yanagi Y; Inoue T; Kadonosono K
    Sci Rep; 2023 Apr; 13(1):5688. PubMed ID: 37029159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
    Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
    Heier JS; Wykoff CC; Waheed NK; Kitchens JW; Patel SS; Vitti R; Perlee L; Chu KW; Leal S; Asmus F; Son V; Schmelter T; Brown DM
    Ophthalmology; 2020 Feb; 127(2):211-220. PubMed ID: 31791663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes.
    Obata S; Kakinoki M; Sawada O; Kawamoto I; Murase M; Ohji M
    J Ocul Pharmacol Ther; 2023 Apr; 39(3):225-228. PubMed ID: 36862540
    [No Abstract]   [Full Text] [Related]  

  • 39. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
    Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.